All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.
Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback